Analyst Price Targets — ICCM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 4, 2026 11:02 am | Scott Henry | Industrial Alliance Securities | $1.00 | $0.30 | TheFly | IceCure Medical initiated with a Buy at Alliance Global |
| August 15, 2025 10:18 am | Yi Chen | H.C. Wainwright | $2.00 | $0.86 | TheFly | IceCure Medical price target lowered to $2 from $2.50 at H.C. Wainwright |
| August 13, 2025 5:58 pm | Kemp Dolliver | Loop Capital Markets | $2.77 | $0.83 | StreetInsider | IceCure Medical Ltd. (ICCM) PT Lowered to $2.77 at Brookline Capital Markets |
| November 29, 2024 11:35 am | Yi Chen | H.C. Wainwright | $2.50 | $0.82 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on IceCure Medical Ltd. (ICCM) |
| May 19, 2022 10:06 am | Ben Haynor | Industrial Alliance Securities | $5.75 | $1.88 | TheFly | IceCure price target lowered to $5.75 from $9.50 at Alliance Global |
Latest News for ICCM
Agreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the highest complete ablation rate among evaluated thermal ablation technologies CAESAREA, Israel, Aug. 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"),…
Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN CAESAREA, Israel, Aug. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing…
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph node metastases CAESAREA, Israel, Aug. 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or…
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash position CAESAREA, Israel, Aug. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ICCM.
U.S. House Trading
No House trades found for ICCM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.